{
    "id": 20822,
    "fullName": "KDM7A - BRAF",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "KDM7A-BRAF (also referred to as JHDM1D-BRAF) results from the fusion of KDM7A and BRAF (PMID: 26314551), which leads to constitutive dimerization of the fusion protein and increased cell proliferation in culture (PMID: 30045926), and has been demonstrated to confer resistance to Fgfr inhibitors as a secondary resistance mutation in the context of FGFR2 amplification in culture (PMID: 30045926). KDM7A-BRAF has been identified in ovarian serous carcinoma (PMID: 26314551) and gastric cancer (PMID: 30045926).",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                },
                {
                    "id": 5129,
                    "pubMedId": 26314551,
                    "title": "The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26314551"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 80853,
        "geneSymbol": "KDM7A",
        "terms": [
            "KDM7A",
            "JHDM1D"
        ]
    },
    "variant": "KDM7A - BRAF",
    "createDate": "04/07/2016",
    "updateDate": "03/27/2020",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 673,
                "geneSymbol": "BRAF",
                "terms": [
                    "BRAF",
                    "B-raf",
                    "B-RAF1",
                    "BRAF1",
                    "NS7",
                    "RAFB1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 21032,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion demonstrated resistance to BGJ398 treatment in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21085,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD-0325901 inhibited growth of gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21091,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ628 reduced Erk phosphorylation and inhibited growth of gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21090,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BGB659 inhibited growth of gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 6245,
                "therapyName": "BGB659",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21034,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion demonstrated resistance to Cediranib (AZD-2171) treatment in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 1001,
                "therapyName": "Cediranib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21033,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion demonstrated resistance to PD173074 treatment in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21084,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited growth of gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21031,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, emergence of a KDM7A-BRAF fusion was identified as the mechanism mediating acquired AZD4547 resistance in a gastric cancer cell line harboring an FGFR2 amplification in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21083,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RO4987655 reduced Erk phosphorylation and inhibited growth of gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 903,
                "therapyName": "RO4987655",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21092,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 reduced Erk phosphorylation and inhibited growth of gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21067,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion demonstrated decreased sensitivity to Zelboraf (vemurafenib) treatment in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21086,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion were not sensitive to Pictilisib (GDC-0941) treatment in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21068,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion demonstrated decreased sensitivity to PLX4720 treatment in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21089,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, gastric cancer cell lines harboring an FGFR2 amplification and a KDM7A-BRAF fusion were not sensitive to MK2206 treatment in culture (PMID: 30045926).",
            "molecularProfile": {
                "id": 35491,
                "profileName": "KDM7A - BRAF FGFR2 amp"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 18258,
                    "pubMedId": 30045926,
                    "title": "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30045926"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 21321,
            "profileName": "KDM7A - BRAF",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35491,
            "profileName": "KDM7A - BRAF FGFR2 amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}